Intramyocardial protein therapy with vascular endothelial growth factor (VEGF-165) induces functional angiogenesis in rat senescent myocardium

Journal of Physiology and Pharmacology

Volumn 61, Issue 6, 2010, Pages 651-661

  Besse, S ^a,b   Boucher, F ^c   Linguet, G ^a   Riou, L ^d   De Leiris, J ^c   Riou, B ^e   Dimastromatteo, J ^d   Comte, R ^a   Courty, J ^a   Delbe, J ^a  

^a Universite Paris Est ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LABORATOIRE TIMC IMAG   (France)

^d French Clinical Research Infrastructure Network   (France)

^e Institute OfCardiometabolism and Nutrition   (France)

Author keywords

Aging; Cardiac hypertrophy; Heart failure; Myocardium; Protein therapy angiogenesis; Vascular endothelial growth factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN I; ANGIOTENSIN II; VASCULOTROPIN 165;

ANGIOGENESIS; ARTICLE; CAPILLARY DENSITY; CELL PROLIFERATION; DIASTOLIC BLOOD PRESSURE; DOWN REGULATION; DRUG ACTIVITY; EXTRACELLULAR MATRIX; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NEOVASCULARIZATION (PATHOLOGY); NERVE SPROUTING; PROTEIN PHOSPHORYLATION; SENESCENCE; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; ANIMALS; CORONARY VESSELS; DOWN-REGULATION; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79251480430     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Masoudi FA, Havranek EP, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail Rev 2002; 7: 9-16.
2. Hachamovitch R, Wicker P, Capasso JM, Anversa P. Alterations of coronary blood flow and reserve with aging in Fischer 344 rats. Am J Physiol 1989; 256: H66-H73.
3. Besse S, Bulteau AL, Boucher F, Riou B, Swynghedauw B, de Leiris J. Antioxidant treatment prevents cardiac protein oxidation after ischemia-reperfusion and improves myocardial function and coronary perfusion in senescent hearts. J Physiol Pharmacol 2006; 57: 541-552.
4. Goldspink DF, Burniston JG, Tan LB. Cardiomyocyte death and the ageing and failing heart. Exp Physiol 2003; 88: 447-458.
5. Edelberg JM, Reed MJ. Aging and angiogenesis. Front Biosci 2003; 8: s1199-s1209.
6. Ahluwalia A, Li A, Cheng G, Deng X, Tarnawski AS. Reduced ghrelin in endothelial cells plays important mechanistic role in aging-related impairment of angiogenesis. J Physiol Pharmacol 2009; 60(2): 29-34.
7. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
8. Christman KL, Fang Q, Kim AJ, et al. Pleiotrophin induces formation of functional neovasculature in vivo. Biochem Biophys Res Commun 2005; 332: 1146-1152.
9. Tomanek RJ, Zheng W, Yue X. Growth factor activation in myocardial vascularization: therapeutic implications. Mol Cell Biochem 2004; 264: 3-11.
10. Friehs I, Moran AM, Stamm C, et al. Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury. Ann Thorac Surg 2004; 77: 2004-2010; discussion: 2011.
11. Edelberg JM, Lee SH, Kaur M, et al. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 2002; 105: 608-613.
12. Maulik N, Thirunavukkarasu M. Growth factors and cell therapy in myocardial regeneration. J Mol Cell Cardiol 2008; 44: 219-227.
13. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor- specific vascular endothelial growth factor mutants. J Biol Chem 2001; 276: 3222-3230.
14. Banai S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994; 89: 2183-2189.
15. Bougioukas I, Didilis V, Ypsilantis P, et al. Intramyocardial injection of low-dose basic fibroblast growth factor or vascular endothelial growth factor induces angiogenesis in the infarcted rabbit myocardium. Cardiovasc Pathol 2007; 16: 63-68.
16. Xaymardan M, Zheng J, Duignan I, et al. Senescent impairment in synergistic cytokine pathways that provide rapid cardioprotection in the rat heart. J Exp Med 2004; 199: 797-804.
17. Iemitsu M, Maeda S, Jesmin S, Otsuki T, Miyauchi T. Exercise training improves aging-induced downregulation of VEGF angiogenic signaling cascade in hearts. Am J Physiol Heart Circ Physiol 2006; 291: H1290-H1298.
18. Zheng J, Chin A, Duignan I, Won KH, Hong MK, Edelberg JM. Growth factor-mediated reversal of senescent dysfunction of ischemia-induced cardioprotection. Am J Physiol Heart Circ Physiol 2006; 290: H525-H530.
19. Swynghedauw B, Besse S, Assayag P, et al. Molecular and cellular biology of the senescent hypertrophied and failing heart. Am J Cardiol 1995;76: 2D-7D.
20. Assayag P, Charlemagne D, de Leiris J, et al. Senescent heart compared with pressure overload-induced hypertrophy. Hypertension 1997; 29: 15-21.
21. Plouet J, Moro F, Bertagnolli S, et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272: 13390-13396.
22. Le Page C, Noirez P, Courty J, Riou B, Swynghedauw B, Besse S. Exercise training improves functional post- ischemic recovery in senescent heart. Exp Gerontol 2009; 44: 177-182.
23. Vacherot F, Delbe J, Heroult M, Barritault D, Fernig DG, Courty J. Glycosaminoglycans differentially bind HARP and modulate its biological activity. J Biol Chem 1999; 274: 7741-7747.
24. Zhu WH, Nicosia RF. The thin prep rat aortic ring assay: a modified method for the characterization of angiogenesis in whole mounts. Angiogenesis 2002; 5: 81-86.
25. Post MJ, Laham R, Sellke FW, Simons M. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 2001; 49: 522-531.
26. Zhang J, Ding L, Zhao Y, et al. Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction. Circulation 2009; 119: 1776-1784.
27. Sancey L, Ardisson V, Riou LM, et al. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol Imaging 2007; 34: 2037-2047.
28. Dor Y, Djonov V, Keshet E. Induction of vascular networks in adult organs: implications to proangiogenic therapy. Ann NY Acad Sci 2003; 995: 208-216.
29. Dimastromatteo J, Riou LM, Ahmadi M, et al. In vivo molecular imaging of myocardial angiogenesis using the alpha(v)beta3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol 2010; 17: 435-443.
30. Uchida N, Nagai K, Sakurada Y, Shirota K. Distribution of VEGF and flt-1 in the normal dog tissues. J Vet Med Sci 2008; 70: 1273-1276.
31. Zhu WH, Iurlaro M, MacIntyre A, Fogel E, Nicosia RF. The mouse aorta model: influence of genetic background and aging on bFGF- and VEGF-induced angiogenic sprouting. Angiogenesis 2003; 6: 193-199.
32. Tuo QH, Zeng H, Stinnett A, et al. Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol 2008; 294: H2547-H2557.
33. Sandhu R, Teichert-Kuliszewska K, Nag S, et al. Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat. Cardiovasc Res 2004; 64: 115-124.
34. Anversa P, Li P, Sonnenblick EH, Olivetti G. Effects of aging on quantitative structural properties of coronary vasculature and microvasculature in rats. Am J Physiol 1994; 267: H1062-H1073.
35. Thomas M, Augustin HG. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009; 12: 125-137.
36. Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, Zioncheck TF. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998; 273: 29979-29985.
37. Lloyd PG, Prior BM, Yang HT, Terjung RL. Angiogenic growth factor expression in rat skeletal muscle in response to exercise training. Am J Physiol Heart Circ Physiol 2003; 284: H1668-H1678.
38. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005; 115: 2108-2118.
39. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol 2008; 6: 292-300.
40. Toyota E, Matsunaga T, Chilian WM. Myocardial angiogenesis. Mol Cell Biochem 2004; 264: 35-44.
41. Arthur WT, Vernon RB, Sage EH, Reed MJ. Growth factors reverse the impaired sprouting of microvessels from aged mice. Microvasc Res 1998; 55: 260-270.
42. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007; 19: 2003-2012.
43. Davis GE, Saunders WB. Molecular balance of capillary tube formation versus regression in wound repair: role of matrix metalloproteinases and their inhibitors. J Investig Dermatol Symp Proc 2006; 11: 44-56.
44. Ferrarini M, Arsic N, Recchia FA, et al. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 2006; 98: 954-961.
45. Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose- dependent effect. Circulation 2000; 101: 118-121.
46. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102: 898-901.
47. Epstein SE, Kornowski R, Fuchs S, Dvorak HF. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation 2001; 104: 115-119.
48. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49: 1015-1026.
49. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107: 1359-1365.
50. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4: 1317-1326.
51. Wijelath ES, Rahman S, Namekata M, et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 2006; 99: 853-860.
52. Wilder RL. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 2002; 61(Suppl 2): ii96-ii99.
53. Stewart DJ, Kutryk MJ, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009; 17: 1109-1115.